Success Metrics

Clinical Success Rate
91.7%

Based on 11 completed trials

Completion Rate
92%(11/12)
Active Trials
0(0%)
Results Posted
45%(5 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
6
50%
Ph phase_4
6
50%

Phase Distribution

0

Early Stage

0

Mid Stage

12

Late Stage

Phase Distribution12 total trials
Phase 3Large-scale testing
6(50.0%)
Phase 4Post-market surveillance
6(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Terminated(1)

Detailed Status

Completed11
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
91.7%
Most Advanced
Phase 4

Trials by Phase

Phase 36 (50.0%)
Phase 46 (50.0%)

Trials by Status

terminated18%
completed1192%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_4

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

NCT03840837
completedphase_3

Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI

NCT01670526
completedphase_3

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

NCT00099242
completedphase_4

Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.

NCT00731224
completedphase_3

An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

NCT00219232
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03840837Phase 4

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

Completed
NCT01670526Phase 3

Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI

Completed
NCT00099242Phase 3

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Completed
NCT00731224Phase 4

Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.

Completed
NCT00219232Phase 3

An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Completed
NCT01529619Phase 4

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Completed
NCT01487317Phase 3

Rivastigmine in the Management of Delirium

Completed
NCT00423085Phase 3

Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

Completed
NCT00881205Phase 4

Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment

Terminated
NCT00623103Phase 3

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

Completed
NCT00622713Phase 4

A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)

Completed
NCT01025466Phase 4

Exelon Patch and Combination With Memantine Comparative Trial

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12